A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Study phase (if other): Ib/2
Primary disease category: Cancer
Sponsor: Dynavax
Projected enrollment dates: January 2017 to December 2019
Official study title: A Phase 1b/2, Open-label, Multicenter, Dose-escalation andExpansion Trial of Intratumoral SD-101 in Combination WithPembrolizumab in Patients With Metastatic Melanoma or Recurrentor Metastatic Head and Neck Squamous Cell Carcinoma
ClinicalTrials.gov page:
http://www.clinicaltrials.gov/show/NCT02521870